EP2123270A1 - Iron metabolism-improving agent - Google Patents
Iron metabolism-improving agent Download PDFInfo
- Publication number
- EP2123270A1 EP2123270A1 EP07850340A EP07850340A EP2123270A1 EP 2123270 A1 EP2123270 A1 EP 2123270A1 EP 07850340 A EP07850340 A EP 07850340A EP 07850340 A EP07850340 A EP 07850340A EP 2123270 A1 EP2123270 A1 EP 2123270A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- iron
- iron metabolism
- improving agent
- citric acid
- dialysate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Definitions
- the present invention relates to iron metabolism-improving agents that improve iron metabolism in the living body, and more specifically, to the iron metabolism-improving agent that improves iron metabolism in a chronic renal failure patient who receives blood purification therapy such as hemodialysis, hemofiltration and hemodiafiltration.
- the present invention relates to methods for improving iron metabolism in a chronic renal failure patient who receives blood purification therapy such as hemodialysis, hemofiltration and hemodiafiltration, by administration of above iron metabolism-improving agents; and more specifically, to a method for improving iron metabolism employing a dialysate and/or a substitution fluid that contain above iron metabolism-improving agents.
- the present invention relates to blood purification methods including hemodialysis and hemodiafiltration in a chronic renal failure patient employing dialysates containing above iron metabolism improving agents, and to blood purification methods including hemodiafiltration and hemofiltration in a chronic renal failure patient employing substitution fluids containing above iron metabolism-improving agents.
- QOL quality of life
- EPO erythropoietin
- Renal anemia that occurs in chronic renal failure patients receiving blood purification therapy is the pathology of decreased hemopoiesis in the bone marrow resulting from relative underproduction of erythropoietin in renal tissues due to renal dysfunction.
- a treatment method for renal anemia is administration of recombinant human erythropoietin (rHuEPO) preparations.
- rHuEPO preparations are also used for renal failure patients during the conservative period before introduction of dialysis.
- anemia is not improved despite administration of rHuEPO preparations because of reduced hematopoietic response to EPO-this is EPO-resistant renal anemia, mainly induced by iron deficiency in the bone marrow.
- Non-patent literature 1 The present inventors have revealed the existence of iron metabolic abnormality in dialysis patients and a part of its mechanism. That is, while the serum iron levels of hemodialysis patients were lower than those of healthy subjects, the serum ferritin levels of hemodialysis patients were significantly higher than those of healthy subjects. In addition, the polymorphonuclear leukocyte iron levels of above hemodialysis patients were about 3 times higher and their ferritin levels were about 1.5 times higher than those of healthy subjects. In evaluation only in patients with lower serum ferritin levels , similar elevations of intracellular iron concentrations were observed. Hence, the present inventors observed that the polymorphonuclear leukocyte iron levels were enhanced notwithstanding serum ferritin levels in dialysis patients.
- Iron transport proteins are considered to relate to intracellular iron metabolism. There have been new findings regarding iron transport proteins at the cellular level, especially in duodenal and reticuloendothelial cells.
- Well-known proteins that take up iron into cells are transferrin receptor (TfR), which takes up ferric (Fe 3+ )-binding transferrin, divalent metal transporter 1 (DMT1), which transports ferrous (Fe 2+ ), and ferroportin 1 (FP1), which exports iron out of cells.
- TfR transferrin receptor
- DMT1 divalent metal transporter 1
- FP1 ferroportin 1
- the present inventors have also revealed the relationship between increased intracellular iron concentrations and iron-transport proteins in polymorphonuclear leukocytes (Non-patent literature 1). That is, it was confirmed that TfR relates to the iron uptake into polymorphonuclear leukocytes and FP1 relates to the iron export out of polymorphonuclear leukocytes.
- the present inventors have revealed at the mRNA level as well as the protein level that the expression of TfR, an iron-uptake protein, is increased and, contrarily, the expression of FP1, an iron-exporting protein, is decreased in the polymorphonuclear leukocytes of hemodialysis patients compared to healthy subjects.
- iron-transport proteins are expressed in the whole-body cells, presumably similar changes of iron-transport protein expression to the changes in polymorphonuclear leukocytes of dialysis patients may occur in the reticuloendothelial system.
- the most important iron metabolism in the living body is the regenerating system where iron is recycled for hematopoiesis at the bone marrow by, first, engulfment of senescent erythrocytes in the reticuloendothelial system, followed by extraction of iron from hemoglobin.
- Non-patent literature 4 inflammatory cytokines have received attention as a factor of iron transport protein dysregulation in dialysis patients.
- the present inventors have investigated for the influence of inflammatory cytokines on iron transport proteins employing human-monocyte-derived cultured cells (Non-patent literature 5). As a result, increased expression of TfR and DMT1 as well as decreased expression of FP1 were observed at the mRNA and protein levels. In addition, it was observed that similar changes occurred by stimulation of cytokines in the iron-preloaded condition. Hence, it was indicated that cytokines induce iron transport protein dysregulation in the reticuloendothelial system notwithstanding the intracellular iron concentration.
- IRP1 iron-metabolism-controlling proteins
- IRP1 binds IRE (iron responsive element) existing in the mRNAs of iron transport proteins under the iron deficient condition to inhibit decay of mRNAs of TfR and DMT1 as well as inhibit translation initiation of mRNAs of FP1 (Non-patent literature 6).
- IRP1 is known to activate aconitase when the intracellular iron concentration is high, citric acid can correct the iron transport protein abnormality through reduction of binding between IRP1 and IRE as a result of enhanced aconitase activity.
- iron recycle disorder due to "iron enclosure" in the reticuloendothelial system resulting from iron transport protein dysregulation in the reticuloendothelial cultivated cells-like in polymorphonuclear leukocytes-induced by hypercytokinemia developed in dialysis patients.
- this iron recycle disorder can be considered to play a key role in the onset and development of various complications which affect prognosis.
- prevention of hypercytokinemia or correction of iron transport protein dysregulation can release "iron enclosure" in the reticuloendothelial system and enhance serum iron concentrations to improve iron recycle in chronic renal failure patients receiving blood purification therapy such as hemodialysis, hemofiltration and hemodiafiltration, and that eventually EPO-resistant renal anemia can be improved and risks of complications can be avoided to improve QOL as well as prognosis of patients.
- the present invention has as an object to provide iron metabolism-improving agents that improve iron metabolism in chronic renal failure patients, and more specially, in those who receive blood purification therapy such as hemodialysis , hemofiltration and hemodiafiltration.
- the present invention also has as another object to provide methods for improving iron metabolism in a chronic renal failure patient who receives blood purification therapy such as hemodialysis, hemofiltration and hemodiafiltration, by administration of iron metabolism-improving agents provided by the present invention, and more specifically, to provide a method for improving iron metabolism employing a dialysate and/or a substitution fluid that contain above iron metabolism-improving agents.
- the present invention has as another object to provide methods for blood purification including hemodialysis and hemodiafiltration in a chronic renal failure patient employing dialysates that contain above-mentioned iron metabolism-improving agents, and to provide methods for blood purification including hemodiafiltration and hemofiltration in a chronic renal failure patient employing substitution fluids that contain above-mentioned iron metabolism-improving agents.
- an embodiment of the present invention comprises:
- an embodiment of the invention comprises:
- the iron metabolism-improving agent provided by the present invention contains citric acid and/or a citrate salt, and more specifically, contains citric acid and/or a citrate salt as electrolytes; and one of efficacies thereof is improvement of abnormal iron recycle induced by renal failure in a chronic renal failure patient receiving blood purification therapy. Furthermore, the iron metabolism-improving agent provided by the present invention recovers the recycle system of iron metabolism to allow iron to be recycled and eventually prevents hypercytokinemia simultaneously correcting the internal iron transport protein dysregulation in the living body. Hence, it is one of excellent advantages of the present invention that improvement of EPO-resistant renal anemia in chronic renal failure patients by the iron metabolism-improving agent provided by the invention reduces risks of onset of complications as well as improves QOL and prognosis of patients.
- the iron metabolism-improving agent provided by the present invention contains citric acid and/or a citrate salt, and specifically, contains citric acid and/or a citrate salt as electrolytes. More specifically, the iron metabolism-improving agent provided by the present invention is characterized in that it does not contain acetic acid and/or an acetate salt and contains citric acid and/or a citrate salt as electrolytes, and additionally, contains another/other electrolyte/electrolytes and glucose solely or in combination.
- the iron metabolism-improving agent provided by the invention is administered in a formulation of a dialysate or a substitution fluid.
- a dialysate or a substitution fluid is a bicarbonate dialysate or a bicarbonate substitution fluid that contains sodium bicarbonate of bicarbonate ions as alkalizer.
- a preferable embodiment of the iron metabolism-improving agent provided by the present invention is a dialysate so-called dialysis preparation "A” comprising electrolytes, pH adjusting agents and/or glucose; the dialysis preparation "A” is diluted, for administration, with a diluting water or, preferably, with so-called dialysis preparation "B” comprising sodium hydrogencarbonate of bicarbonate irons.
- Another preferable embodiment of the iron metabolism-improving agent provided by the present invention is a substitution fluid so-called dialysis preparation "B” comprising electrolytes, pH adjusting agents and/or glucose; the dialysis preparation “B” is mixed, for administration, with a dialysis preparation "A” comprising electrolytes, pH adjusting agent and sodium hydrogencarbonate.
- Preferable electrolytes used in the iron metabolism-improving agent provided by the present invention in addition to citric acid and/or a citrate salt such as sodium citrate include, for example, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, sodium lactate, potassium lactate and calcium lactate.
- Especially preferable electrolytes include sodium chloride, potassium chloride, calcium chloride, magnesium chloride and sodium citrate.
- the iron metabolism-improving agent provided by the present invention contains glucose and pH adjusting agents to suitably control the pH of a dialysate and/or a substitution fluid after preparation.
- Preferable pH adjusting agents include citric acid, lactic acid, hydrochloric acid, malic acid, ascorbic acid, tartaric acid and sodium hydroxide.
- Especially preferable pH adjusting agents include citric acid and hydrochloric acid.
- the iron metabolism-improving agent provided by the present invention contains above-mentioned components preferably at the concentrations as described below when suitably diluted and mixed to be a bicarbonate dialysate or a bicarbonate substitution fluid.
- insoluble compounds are produced because of the existence of citric acid and/or a citrate salt such as sodium citrate. However, production of such insoluble compounds is prevented by citric acid with controlling a pH at low level.
- citric acid suppresses generation of precipitates.
- electrolytes in a dialysis preparation "A” or a substitution fluid “B” are mixed with sodium bicarbonate of bicarbonate irons in a dialysis preparation "B” or a substitution fluid “A”
- reaction between bicarbonate ions and calcium or magnesium ions produces insoluble metal carbonates. Therefore, these "A” and "B” are mixed and diluted just before use as a dialysate for artificial kidney.
- An advantage of the present invention is that citric acid's precipitate-suppressing effect prolongs the stability of dialysate.
- citric acid and/or a citrate salt are contained in the iron metabolism-improving agent in the amount that allows a pH of prepared dialysate to range about between 2.2 and 2.9, and that allows a citrate ion concentration to usually range between 0.02 and 5 mEq/L as described above.
- the iron metabolism-improving agent provided by the present invention is characterized by acetic-acid free formulation.
- a dialysate and/or a substitution fluid formulated with the iron metabolism-improving agent provided by the present invention are physiologically more compatible because sodium bicarbonate is used as the only alkalizer.
- the iron metabolism-improving agent provided by the present invention is capable of correcting iron transport protein dysregulation through reduction of IRP1-IRE binding as a result of enhanced aconitase activity owing to action of citric acid and/or a citrate salt contained therein.
- the iron metabolism-improving agent provided by the present invention is also capable of correcting iron transport protein dysregulation through prevention of hypercytokinemia in dialysis patients owing to acetic-acid free formulation thereof. Consequently, "iron enclosure" in the reticuloendothelial system is released, and then, serum iron concentration increases to improve iron metabolism abnormality, which, as a result, improves iron recycle contributing largely to improvement of EPO-resistant renal anemia.
- the above-mentioned points are some of especially unique features of the iron metabolism-improving agent provided by the present invention.
- iron metabolism-improving agent in addition to formulations into dialysates and substitution fluids, other available formulations of the iron metabolism-improving agent provided by the invention include liquid, elixir, capsule, granule, pill, percutaneous absorption, suspension or emulsion, suppository, powder, alcoholic, tablet, syrup, injection, adhesive skin patch and lemonade; mixed with carriers, excipients, diluting agents and other agents acceptable for pharmaceutical products.
- the iron metabolism-improving agent provided by the present invention can be taken orally (ingested) formulated with suitable excipients into, for example, powder, granule, tablet, liquid (including beverage, and jelly), candy and so on.
- Pentobarbital sodium (30 mg/kg) was administered via cephalic vein for introduction.
- pentobarbital sodium was appropriately administered intravenously with an infusion pump to maintain anesthesia.
- Blood access was created by an 8 Fr catheter filled with physiological saline mixed with heparin (10 units/mL) implanted into femoral arteriovenous fistula. Then, endotracheal intubation was performed to set a ventilator for respiratory care.
- a single-patient hemodiafiltration system DBG-01 (by Nikkiso Co., Ltd.), was used for hemodialysis.
- DBG-01 for filter membrane and a blood tubing set, PS-0. 6UW and a pediatric blood tubing set were used, respectively.
- a dialysate provided by the present invention prepared in accordance with the prescription in the table 1 below was used.
- commercial dialysate "AK-Solita TM ⁇ DL" was used. Both groups had three cases, respectively.
- Hemodialysis was performed continuously for 4 hours at a blood flow rate of 100 mL/min and at a dialysate flow rate of 300 mL/min without body fluid removal.
- 100 units/kg of heparin was administered intravenously in advance of dialysis initiation, and after that, additionally 50 units/kg of heparin was administered intravenously every 1 hour.
- pentobarbital sodium was appropriately administered intravenously with an infusion pump to maintain anesthesia.
- UIBC unsaturated iron binding capacity
- Re plasma creatinine
- BUN blood urea nitrogen
- TIBC Total iron binding capacity
- tissue analysis a comparison was performed among two experimental groups consisting of one group administered with the dialysate provided by the present invention and the other group administered with the commercial dialysate, an untreated control group consisting of three healthy cases, and a renal failure control group consisting of three cases untreated with dialysis.
- Results of citric acid concentration, serum iron concentration, UIBC and TIBC are shown in Figures 1-4 .
- the acetic acid concentration results after two hours of dialysis initiation are shown in Table 2.
- the plasma Cre and BUN concentrations of dogs in the renal failure group markedly increased after two days of bilateral ureteral ligation before dialysis initiation. The onset of renal failure was confirmed.
- the plasma Cre and BUN concentrations having increased due to renal failure decreased immediately after dialysis in both groups administered with the dialysate provided by the invention and the commercial dialysate.
- UIBC values after dialysis were significantly lower in both groups administered with the dialysate provided by the invention and the commercial dialysate than before dialysis.
- the splenic tissue ferritin staining intensity decreased more, and fewer cells were stained in the group dialyzed with the dialysate provided by the invention than the group dialyzed with the commercial dialysate.
- Above analyses of tissues indicate that iron is enclosed in organs under renal failure state and dialysis can release the iron enclosure, and that splenic iron enclosure is markedly released by the dialysate provided by the invention compared to the commercial dialysate. Accordingly, it is indicated that dialysis with a dialysate provided by the invention can be effective in improvement of declined iron recycle rate due to renal failure.
- CD(SD) rats Eight-week-old male CD(SD) rats (body weight: about 300 g) were used in the groups as shown in Table 3.
- CVC central venous catheter
- 1 mL of blood was collected by CVC.
- physiological saline or a 4.5% (w/v) sodium citrate solution was administered by CVC at 0.25 mL/h for 4 hours in the second and third groups in Table 3, and 1 mL of blood was collected by CVC immediately after termination of administration.
- Collected blood was centrifuged in a refrigerated centrifuge to measure plasma creatinine (Cre), blood urea nitrogen (BUN), iron and citric acid.
- FIG. 6 and 7 shows results of citric acid and iron concentrations.
- Plasma Cre and BUN concentrations increased markedly at 24 hours after extirpation of bilateral kidneys, and onset of renal failure was confirmed.
- Plasma citric acid concentrations were 5.27 ⁇ 1.23 mg/dL in the first group but increased to 16.38 ⁇ 9.49 mg/dL and 17.11 ⁇ 18.64 mg/dL in the second and third groups respectively due to extirpation of bilateral kidneys ( Figure 6 ).
- the difference of plasma citric acid concentrations between before and after administration in the third group was 21.08 ⁇ 13.18 mg/dL. Enhancement of plasma citric acid concentrations by administration of citric acid was observed.
- physiological saline or a 4.5% (w/v) sodium citrate solution was administered by CVC at 1.0 mL/h continuously, and 1 mL of blood was collected by CVC immediately after termination of dialysis. Collected blood was centrifuged in a refrigerated centrifuge to measure plasma creatinine (Cre), blood urea nitrogen (BUN), iron and citric acid.
- FIGs 8 and 9 show results of citric acid and iron concentrations.
- Plasma Cre and BUN concentrations increased markedly at the second day after extirpation of bilateral kidneys before dialysis, and onset of renal failure was confirmed. Increased plasma Cre and BUN concentrations decreased immediately by dialysis.
- Plasma citric acid concentrations were 5.33 mg/dL in the first group but increased to 9.87 mg/dL in the second group due to extirpation of bilateral kidneys, while plasma citric acid concentrations in the third group were 5.33 mg/dL at the same level as the first group ( Figure 8 ).
- the difference of plasma citric acid concentrations between before and after citric acid administration was 26.49 mg/dL.
- Preparation A (component and amount per 10 L) Sodium chloride 2,148.0 g Potassium chloride 52.0 g Calcium chloride 77.0 g Magnesium chloride 36.0 g Glucose 525.0 g Citric acid 34.3 g Sodium citrate 10.3 g
- Preparation B (component and amount per 12.6 L) Sodium hydrogencarbonate 1,030.0 g
- Preparation A (component and amount per 1,010 mL) Sodium chloride 12.34 g Potassium chloride 0.30 g Sodium hydrogencarbonate 5.94 g
- Preparation B (component and amount per 1,010 mL) Calcium chloride 519.8 mg Magnesium chloride 205.4 mg Glucose 2.02 g Citric acid 198.0 mg Sodium citrate 59.4 mg
- an acetic acid- and/or acetate salt-free iron metabolism improving agent containing citric acid and/or a citrate salt prevents hypercytokinemia, corrects iron transport protein dysregulation and releases "iron enclosure" in the reticuloendothelial system, which leads to enhancement of serum iron concentrations and improvement in iron recycle in a chronic renal failure patient receiving blood purification therapy.
- EPO-resistant renal anemia of such a patient is improved, and complication occurrence risks are reduced.
- the present invention has great medical advantages and usefulness for its contribution to improvement of QOL and prognosis of patients.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- External Artificial Organs (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
- The present invention relates to iron metabolism-improving agents that improve iron metabolism in the living body, and more specifically, to the iron metabolism-improving agent that improves iron metabolism in a chronic renal failure patient who receives blood purification therapy such as hemodialysis, hemofiltration and hemodiafiltration.
- Further, the present invention relates to methods for improving iron metabolism in a chronic renal failure patient who receives blood purification therapy such as hemodialysis, hemofiltration and hemodiafiltration, by administration of above iron metabolism-improving agents; and more specifically, to a method for improving iron metabolism employing a dialysate and/or a substitution fluid that contain above iron metabolism-improving agents.
- Furthermore, the present invention relates to blood purification methods including hemodialysis and hemodiafiltration in a chronic renal failure patient employing dialysates containing above iron metabolism improving agents, and to blood purification methods including hemodiafiltration and hemofiltration in a chronic renal failure patient employing substitution fluids containing above iron metabolism-improving agents.
- Chronic renal failure patients who receive blood purification therapy, typically hemodialysis, suffer from lowered quality of life (QOL), hospitalization and high mortality rates induced by various complications. It is well known that causes of such complications include chronic inflammatory state, nutritional deficiencies, arteriosclerosis and erythropoietin (EPO) resistant renal anemia, and that interrelation among them deteriorates prognosis.
Although a comprehensive mechanism causing these pathologies is not known yet, a suspected cause is iron metabolic abnormality induced by renal failure, that is, cellular dysfunction induced by iron accumulation in various organs and tissues as well as increased oxidative stress due to iron-mediated Fenton reactions. - Renal anemia that occurs in chronic renal failure patients receiving blood purification therapy is the pathology of decreased hemopoiesis in the bone marrow resulting from relative underproduction of erythropoietin in renal tissues due to renal dysfunction. A treatment method for renal anemia is administration of recombinant human erythropoietin (rHuEPO) preparations. Recently, rHuEPO preparations are also used for renal failure patients during the conservative period before introduction of dialysis.
However, there are often cases where anemia is not improved despite administration of rHuEPO preparations because of reduced hematopoietic response to EPO-this is EPO-resistant renal anemia, mainly induced by iron deficiency in the bone marrow. It has been considered that, in chronic renal failure patients, increased demand for iron resulting from enhanced hematopoiesis due to rHuEPO treatments causes iron deficiency in the bone marrow. On the other hand, it is also known the state that anemia is improved by additional administration of iron notwithstanding presumable sufficient iron storage considering the serum ferritin concentration-the state of functional iron deficiency. - The present inventors have revealed the existence of iron metabolic abnormality in dialysis patients and a part of its mechanism (Non-patent literature 1) . That is, while the serum iron levels of hemodialysis patients were lower than those of healthy subjects, the serum ferritin levels of hemodialysis patients were significantly higher than those of healthy subjects. In addition, the polymorphonuclear leukocyte iron levels of above hemodialysis patients were about 3 times higher and their ferritin levels were about 1.5 times higher than those of healthy subjects.
In evaluation only in patients with lower serum ferritin levels , similar elevations of intracellular iron concentrations were observed.
Hence, the present inventors observed that the polymorphonuclear leukocyte iron levels were enhanced notwithstanding serum ferritin levels in dialysis patients. - Iron transport proteins are considered to relate to intracellular iron metabolism. There have been new findings regarding iron transport proteins at the cellular level, especially in duodenal and reticuloendothelial cells. Well-known proteins that take up iron into cells are transferrin receptor (TfR), which takes up ferric (Fe3+)-binding transferrin, divalent metal transporter 1 (DMT1), which transports ferrous (Fe2+), and ferroportin 1 (FP1), which exports iron out of cells.
- The present inventors have also revealed the relationship between increased intracellular iron concentrations and iron-transport proteins in polymorphonuclear leukocytes (Non-patent literature 1). That is, it was confirmed that TfR relates to the iron uptake into polymorphonuclear leukocytes and FP1 relates to the iron export out of polymorphonuclear leukocytes. In addition, the present inventors have revealed at the mRNA level as well as the protein level that the expression of TfR, an iron-uptake protein, is increased and, contrarily, the expression of FP1, an iron-exporting protein, is decreased in the polymorphonuclear leukocytes of hemodialysis patients compared to healthy subjects.
- The above indicates that iron excessively accumulates in polymorphonuclear leukocytes in hemodialysis patients because of the abnormal regulation of above-mentioned iron-transport proteins, that is, an "iron enclosure".
Since iron-transport proteins are expressed in the whole-body cells, presumably similar changes of iron-transport protein expression to the changes in polymorphonuclear leukocytes of dialysis patients may occur in the reticuloendothelial system.
The most important iron metabolism in the living body is the regenerating system where iron is recycled for hematopoiesis at the bone marrow by, first, engulfment of senescent erythrocytes in the reticuloendothelial system, followed by extraction of iron from hemoglobin. Under this system, approximately from 20 to 25 mg of iron is recycled per day. When the "iron enclosure" occurs in the hepatic or splenic reticuloendothelial systems or bone marrow macrophages, the regenerating system of iron metabolism is broken down, which leads to the state of functional iron deficiency where iron is deficient notwithstanding high serum ferritin concentration. - Meantime, many chronic renal failure patients are considered to be chronically in the inflammatory state because their levels of C-reactive protein, an indicator of acute inflammatory response, are high. Heretofore, chronic anemia induced by chronic inflammatory diseases have been reported to be caused by iron recycle disorder due to accumulation of iron in splenic and hepatic macrophages as well as due to the "iron enclosure" in the reticuloendothelial system (Non-patent literature 2).
Moreover, a relationship between a part of EPO-resistant renal anemia and chronic inflammatory state has been suggested (Non-patent literature 3).
Recently, given the reports pointing out a relationship between the pathology of anemia induced by chronic inflammatory diseases and inflammatory cytokines (Non-patent literature 4), inflammatory cytokines have received attention as a factor of iron transport protein dysregulation in dialysis patients. - The present inventors have investigated for the influence of inflammatory cytokines on iron transport proteins employing human-monocyte-derived cultured cells (Non-patent literature 5). As a result, increased expression of TfR and DMT1 as well as decreased expression of FP1 were observed at the mRNA and protein levels. In addition, it was observed that similar changes occurred by stimulation of cytokines in the iron-preloaded condition. Hence, it was indicated that cytokines induce iron transport protein dysregulation in the reticuloendothelial system notwithstanding the intracellular iron concentration.
- Since conventional dialysis preparations on the market contain a slight amount (from 8 to 12 mEq/L) of acetic acid for the purpose of stabilization, it has been indicated that acetic acid can promote hypercytokinemia because of its stimulation to monocytes. In the meantime, aconitase, a citric acid-converting enzyme, has iron-sulfur complexes at the active center, and, when the intracellular iron concentration is low, the iron-sulfur complexes decompose to lower the enzyme activity. Also, it has been reported that, among iron-metabolism-controlling proteins (IRPs: iron regulatory proteins) existing in the cytoplasm, IRP1 binds IRE (iron responsive element) existing in the mRNAs of iron transport proteins under the iron deficient condition to inhibit decay of mRNAs of TfR and DMT1 as well as inhibit translation initiation of mRNAs of FP1 (Non-patent literature 6). Because IRP1 is known to activate aconitase when the intracellular iron concentration is high, citric acid can correct the iron transport protein abnormality through reduction of binding between IRP1 and IRE as a result of enhanced aconitase activity.
- Summarizing the above, a presumable major cause of EPO-resistant renal anemia is the iron recycle disorder due to "iron enclosure" in the reticuloendothelial system resulting from iron transport protein dysregulation in the reticuloendothelial cultivated cells-like in polymorphonuclear leukocytes-induced by hypercytokinemia developed in dialysis patients. Moreover, this iron recycle disorder can be considered to play a key role in the onset and development of various complications which affect prognosis.
- According to the above, it is contemplated that prevention of hypercytokinemia or correction of iron transport protein dysregulation can release "iron enclosure" in the reticuloendothelial system and enhance serum iron concentrations to improve iron recycle in chronic renal failure patients receiving blood purification therapy such as hemodialysis, hemofiltration and hemodiafiltration, and that eventually EPO-resistant renal anemia can be improved and risks of complications can be avoided to improve QOL as well as prognosis of patients.
- Heretofore, however, there has been presented no specific method for improvement of iron metabolism abnormality, that is, excessive iron uptake into cells and suppressed iron export out of cells; or for transfer of iron accumulated in the reticuloendothelial system so as to be recycled in the hematopoietic system in chronic renal failure patients receiving blood purification therapy. Conventionally, add-on therapy of iron preparations to EPO preparations has been considered to be effective as a treatment method for chronic renal failure patients with EPO-resistant renal anemia. However, this is one of methods relying on experience of specialized physicians, and therefore, there is no specifically established treatment method at present.
-
- Non-patent literature 1: Otaki Y, et al.: Am. J. Kidney Dis.: 43, 1030-1039 (2004)
- Non-patent literature 2: Ali M, et al.: Lancet: 20, 652-655 (1982)
- Non-patent literature 3: Barany P: Nephrol. Dial. Tranplant.: 16, 224-227 (2001)
- Non-patent literature 4: Ludwiczek S, et al. : Blood. : 101, 4148-4154 (2003)
- Non-patent literature 5: Nanami M, et al.: Arterioscler Thromb. Vasc. Biol.: 25, 2495-2501 (2005)
- Non-patent literature 6: Hentze MW et al. : Cell: 117, 285-297 (2004)
- In the view of the above problems, the present invention has as an object to provide iron metabolism-improving agents that improve iron metabolism in chronic renal failure patients, and more specially, in those who receive blood purification therapy such as hemodialysis , hemofiltration and hemodiafiltration.
- The present invention also has as another object to provide methods for improving iron metabolism in a chronic renal failure patient who receives blood purification therapy such as hemodialysis, hemofiltration and hemodiafiltration, by administration of iron metabolism-improving agents provided by the present invention, and more specifically, to provide a method for improving iron metabolism employing a dialysate and/or a substitution fluid that contain above iron metabolism-improving agents.
- Further, the present invention has as another object to provide methods for blood purification including hemodialysis and hemodiafiltration in a chronic renal failure patient employing dialysates that contain above-mentioned iron metabolism-improving agents, and to provide methods for blood purification including hemodiafiltration and hemofiltration in a chronic renal failure patient employing substitution fluids that contain above-mentioned iron metabolism-improving agents.
- To solve problems in the conventional art, an embodiment of the present invention comprises:
- (1) An iron metabolism-improving agent comprising citric acid and/or a citrate salt;
- (2) The iron metabolism-improving agent of above (1) comprising citric acid and/or a citrate salt as electrolytes;
- (3) The iron metabolism-improving agent of above (1) or (2) comprising no acetic acid and/or an acetate salt and comprising citric acid and/or a citrate salt as electrolytes; and,
- (4) The iron metabolism-improving agent of above (1), (2) or (3) comprising citric acid and/or a citrate salt as electrolytes, and further comprising solely or in combination another/other electrolyte/electrolytes and glucose.
- More specifically, an embodiment of the invention comprises:
- (5) The iron metabolism-improving agent of any one of above (1) to (4) formulated into a dialysate; and
- (6) The iron metabolism-improving agent of any one of above (1) to (4) formulated into a substitution fluid.
- Another embodiment of the invention comprises:
- (7) A method for improving iron metabolism in a chronic renal failure patient receiving blood purification therapy such as hemodialysis, hemofiltration and hemodiafiltration, by administration of the iron metabolism-improving agent of any one of above (1) to (4); and more specifically,
- (8) An iron metabolism improving method in a chronic renal failure patient receiving blood purification therapy such as hemodialysis, hemofiltration and hemodiafiltration employing a dialysate and/or a substitution fluid that contain the iron metabolism-improving agent of above (5) or (6).
- Another embodiment of the invention comprises:
- (9) A blood purification method including hemodialysis and hemodiafiltration in a chronic renal failure patient employing a dialysate that contains the iron metabolism-improving agent of above (5); and
- (10) A blood purification method including hemodiafiltration and hemofiltration in a chronic renal failure patient employing a substitution fluid that contains the iron metabolism-improving agent of above (6).
- The iron metabolism-improving agent provided by the present invention contains citric acid and/or a citrate salt, and more specifically, contains citric acid and/or a citrate salt as electrolytes; and one of efficacies thereof is improvement of abnormal iron recycle induced by renal failure in a chronic renal failure patient receiving blood purification therapy.
Furthermore, the iron metabolism-improving agent provided by the present invention recovers the recycle system of iron metabolism to allow iron to be recycled and eventually prevents hypercytokinemia simultaneously correcting the internal iron transport protein dysregulation in the living body.
Hence, it is one of excellent advantages of the present invention that improvement of EPO-resistant renal anemia in chronic renal failure patients by the iron metabolism-improving agent provided by the invention reduces risks of onset of complications as well as improves QOL and prognosis of patients. - As aforementioned, the iron metabolism-improving agent provided by the present invention contains citric acid and/or a citrate salt, and specifically, contains citric acid and/or a citrate salt as electrolytes.
More specifically, the iron metabolism-improving agent provided by the present invention is characterized in that it does not contain acetic acid and/or an acetate salt and contains citric acid and/or a citrate salt as electrolytes, and additionally, contains another/other electrolyte/electrolytes and glucose solely or in combination. - Hence, preferably, the iron metabolism-improving agent provided by the invention is administered in a formulation of a dialysate or a substitution fluid. A preferable embodiment of such a dialysate or a substitution fluid is a bicarbonate dialysate or a bicarbonate substitution fluid that contains sodium bicarbonate of bicarbonate ions as alkalizer.
- In view of the above, a preferable embodiment of the iron metabolism-improving agent provided by the present invention is a dialysate so-called dialysis preparation "A" comprising electrolytes, pH adjusting agents and/or glucose; the dialysis preparation "A" is diluted, for administration, with a diluting water or, preferably, with so-called dialysis preparation "B" comprising sodium hydrogencarbonate of bicarbonate irons. Another preferable embodiment of the iron metabolism-improving agent provided by the present invention is a substitution fluid so-called dialysis preparation "B" comprising electrolytes, pH adjusting agents and/or glucose; the dialysis preparation "B" is mixed, for administration, with a dialysis preparation "A" comprising electrolytes, pH adjusting agent and sodium hydrogencarbonate.
- Preferable electrolytes used in the iron metabolism-improving agent provided by the present invention in addition to citric acid and/or a citrate salt such as sodium citrate include, for example, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, sodium lactate, potassium lactate and calcium lactate. Especially preferable electrolytes include sodium chloride, potassium chloride, calcium chloride, magnesium chloride and sodium citrate.
- In addition to above-mentioned components, the iron metabolism-improving agent provided by the present invention contains glucose and pH adjusting agents to suitably control the pH of a dialysate and/or a substitution fluid after preparation.
Preferable pH adjusting agents include citric acid, lactic acid, hydrochloric acid, malic acid, ascorbic acid, tartaric acid and sodium hydroxide. Especially preferable pH adjusting agents include citric acid and hydrochloric acid.
Accordingly, the iron metabolism-improving agent provided by the present invention contains above-mentioned components preferably at the concentrations as described below when suitably diluted and mixed to be a bicarbonate dialysate or a bicarbonate substitution fluid. -
Sodium ion 120-150 mEq/L Potassium ion 0-5 mEq/L Calcium ion 0-5 mEq/L Magnesium ion 0-2 mEq/L Chloride ion 55-135 mEq/L Bicarbonate ion 20-45 mEq/L Citrate ion 0.02-5 mEq/L Glucose 0-3.0 g/L - When calcium ions are included as an electrolyte in the iron metabolism-improving agent provided by the present invention, insoluble compounds are produced because of the existence of citric acid and/or a citrate salt such as sodium citrate. However, production of such insoluble compounds is prevented by citric acid with controlling a pH at low level.
- Furthermore, use of citric acid suppresses generation of precipitates. When electrolytes in a dialysis preparation "A" or a substitution fluid "B" are mixed with sodium bicarbonate of bicarbonate irons in a dialysis preparation "B" or a substitution fluid "A", reaction between bicarbonate ions and calcium or magnesium ions produces insoluble metal carbonates. Therefore, these "A" and "B" are mixed and diluted just before use as a dialysate for artificial kidney. An advantage of the present invention is that citric acid's precipitate-suppressing effect prolongs the stability of dialysate.
- According to the present invention, preferably citric acid and/or a citrate salt are contained in the iron metabolism-improving agent in the amount that allows a pH of prepared dialysate to range about between 2.2 and 2.9, and that allows a citrate ion concentration to usually range between 0.02 and 5 mEq/L as described above.
- Moreover, against conventional dialysis preparation "A" and substitution fluid "B" containing acetic acid, the iron metabolism-improving agent provided by the present invention is characterized by acetic-acid free formulation. Hence, it is another advantage of the present invention that a dialysate and/or a substitution fluid formulated with the iron metabolism-improving agent provided by the present invention are physiologically more compatible because sodium bicarbonate is used as the only alkalizer.
- The iron metabolism-improving agent provided by the present invention is capable of correcting iron transport protein dysregulation through reduction of IRP1-IRE binding as a result of enhanced aconitase activity owing to action of citric acid and/or a citrate salt contained therein. In addition, the iron metabolism-improving agent provided by the present invention is also capable of correcting iron transport protein dysregulation through prevention of hypercytokinemia in dialysis patients owing to acetic-acid free formulation thereof. Consequently, "iron enclosure" in the reticuloendothelial system is released, and then, serum iron concentration increases to improve iron metabolism abnormality, which, as a result, improves iron recycle contributing largely to improvement of EPO-resistant renal anemia.
The above-mentioned points are some of especially unique features of the iron metabolism-improving agent provided by the present invention. - In addition to formulations into dialysates and substitution fluids, other available formulations of the iron metabolism-improving agent provided by the invention include liquid, elixir, capsule, granule, pill, percutaneous absorption, suspension or emulsion, suppository, powder, alcoholic, tablet, syrup, injection, adhesive skin patch and lemonade; mixed with carriers, excipients, diluting agents and other agents acceptable for pharmaceutical products. Also, the iron metabolism-improving agent provided by the present invention can be taken orally (ingested) formulated with suitable excipients into, for example, powder, granule, tablet, liquid (including beverage, and jelly), candy and so on.
- By way of test and working examples, and not limitation, detailed description of the invention will be set forth.
- Renal failure dogs were dialyzed and effects on iron metabolism were evaluated.
- After 18-hour fasting, male beagle dogs were anesthetized with pentobarbital sodium (30 mg/kg) via cephalic vein and underwent midline laparotomy followed by complete bilateral ureteral ligation.
Dialysis experiment was performed after 2 days of the operation. Pentobarbital sodium (30 mg/kg) was administered via cephalic vein for introduction. During the operation, pentobarbital sodium was appropriately administered intravenously with an infusion pump to maintain anesthesia.
Blood access was created by an 8 Fr catheter filled with physiological saline mixed with heparin (10 units/mL) implanted into femoral arteriovenous fistula. Then, endotracheal intubation was performed to set a ventilator for respiratory care.
A single-patient hemodiafiltration system, DBG-01 (by Nikkiso Co., Ltd.), was used for hemodialysis. For filter membrane and a blood tubing set, PS-0. 6UW and a pediatric blood tubing set were used, respectively. - For a group, a dialysate provided by the present invention prepared in accordance with the prescription in the table 1 below was used. For the other group, commercial dialysate "AK-Solita™ ·DL" was used. Both groups had three cases, respectively.
Hemodialysis was performed continuously for 4 hours at a blood flow rate of 100 mL/min and at a dialysate flow rate of 300 mL/min without body fluid removal.
For prevention of blood coagulation, 100 units/kg of heparin was administered intravenously in advance of dialysis initiation, and after that, additionally 50 units/kg of heparin was administered intravenously every 1 hour.
During dialysis, pentobarbital sodium was appropriately administered intravenously with an infusion pump to maintain anesthesia. - Blood was collected before bilateral ureteral ligation, before dialysis initiation, and at 2 and 4 hours after dialysis initiation. Collected blood was centrifuged in a refrigerated centrifuge to measure serum iron, unsaturated iron binding capacity (UIBC), plasma creatinine (Cre), blood urea nitrogen (BUN), citric acid and acetic acid.
Total iron binding capacity (TIBC) was calculated by adding serum iron to UIBC.
After termination of dialysis, blood was removed through blood access with physiological saline, and then after perfusion, splenic tissues were collected from the dissected animals. The collected tissues were stained with prussian blue stain for iron assessment, and the iron stain percentage was computed by image analysis. In addition, immunohistochemical staining of tissue ferritin was performed for macroscopic observation. For tissue analysis, a comparison was performed among two experimental groups consisting of one group administered with the dialysate provided by the present invention and the other group administered with the commercial dialysate, an untreated control group consisting of three healthy cases, and a renal failure control group consisting of three cases untreated with dialysis. -
Table 1. Component Concentration (mEq/L) Dialysate Provided by the Invention Commercial Dialysate Sodium 140 140 Potassium 2.0 2.0 Calcium 3.0 3.0 Magnesium 1.0 1.0 Chlorine 111 111 Glucose 1.5 1 Hydrogencarbonate 35 25 Acetic acid - 10 Citric acid 1.4 - Sodium citrate 0.3 - - Results of citric acid concentration, serum iron concentration, UIBC and TIBC are shown in
Figures 1-4 .
The acetic acid concentration results after two hours of dialysis initiation are shown in Table 2.
The plasma Cre and BUN concentrations of dogs in the renal failure group markedly increased after two days of bilateral ureteral ligation before dialysis initiation. The onset of renal failure was confirmed.
The plasma Cre and BUN concentrations having increased due to renal failure decreased immediately after dialysis in both groups administered with the dialysate provided by the invention and the commercial dialysate. While the plasma citric acid concentrations of the group administered with dialysate provided by the invention changed at similar levels to before hemodialysis, the plasma citric acid concentrations of the group administered with the commercial dialysate decreased after dialysis (Figure 1 ). In comparison between the groups, citric acid concentrations of the group administered with the dialysate provided by the invention were significantly higher than those of the group administered with the commercial dialysate at 2 and 4 hours after dialysis. While plasma acetic acid was not detected in the group administered with the dialysate provided by the invention during dialysis, the plasma acetic acid concentration of the group administered with the commercial dialysis significantly increased due to dialysis (p<0.05, Table 2). - With respect to iron, the serum iron concentrations having decreased due to renal failure significantly increased by dialysis with the dialysate provided by the invention compared to before dialysis (
Figure 2 ). In contrast, no significant change was observed in the group administered with the commercial dialysate. By the two-way analysis of variance, significant differences of iron concentrations were observed not only depending on duration of dialysis session but also on type of dialysates (from before dialysis through 4 h after dialysis: time, F(2,12)=4.46, p<0.05; dialysate, F(1,12)=9.71, p<0.01, time x dialysate, F(2,12)=1.09, p>0.05). - UIBC values after dialysis were significantly lower in both groups administered with the dialysate provided by the invention and the commercial dialysate than before dialysis. By the two-way analysis of variance, significant differences of UIBC values were observed depending on duration of dialysis session as well as on type of dialysates (from before dialysis through 4 h after dialysis: time, F(2,12)=9.91, p<0.01; dialysate, F(1,12)=7.82, p<0.05, time x dialysate, F(2,12)=0.53, p>0.05:
Figure 3 ). - Because practically no change was observed in TIBC values by dialysis and there was no significant difference between the type of dialysates (
Figure 4 ), the changes in UIBC values were considered to be an effect of changes in serum iron concentrations.
The iron stain percentages in splenic tissues of renal failure groups were higher than those of untreated group. The increased iron stain percentages decreased by dialysis; iron staining was less intense in the group administered with the dialysate provided by the invention than iron staining in the group administered with the commercial dialysate (Figure 5 ). Statistic analysis demonstrated a significant difference in splenic iron stain percentages between the group administered with the dialysate provided by the invention and the group administered with the commercial dialysate (p<0.05).
The splenic tissue ferritin staining intensity decreased more, and fewer cells were stained in the group dialyzed with the dialysate provided by the invention than the group dialyzed with the commercial dialysate.
Above analyses of tissues indicate that iron is enclosed in organs under renal failure state and dialysis can release the iron enclosure, and that splenic iron enclosure is markedly released by the dialysate provided by the invention compared to the commercial dialysate.
Accordingly, it is indicated that dialysis with a dialysate provided by the invention can be effective in improvement of declined iron recycle rate due to renal failure. -
Table 2 Administration Group Plasma Acetic Acid Concentration (mg/dL) Dialysate provided by the invention 0.0 ± 0.0 Commercial dialysate 4.3 ± 0.2 - Effects of citric acid administration on iron metabolism were evaluated in bilaterally nephrectomized rats.
- Eight-week-old male CD(SD) rats (body weight: about 300 g) were used in the groups as shown in Table 3. After intra-peritoneal administration of pentobarbital sodium for anesthesia, bilateral total kidneys were extirpated from the back of rat (Rats in the first group in Table 3 were untreated.) and a central venous catheter (CVC) was placed.
At about 24 hours after the operation, 1 mL of blood was collected by CVC. Immediately after blood collection, physiological saline or a 4.5% (w/v) sodium citrate solution was administered by CVC at 0.25 mL/h for 4 hours in the second and third groups in Table 3, and 1 mL of blood was collected by CVC immediately after termination of administration.
Collected blood was centrifuged in a refrigerated centrifuge to measure plasma creatinine (Cre), blood urea nitrogen (BUN), iron and citric acid. -
Table 3 Group Experimental Group Administered Solution Number of Animals 1 Untreated - 3 2 Bilateral kidney extirpation + Saline Physiological saline 6 3 Bilateral kidney extirpation + 4.5% Cit. 4.5% (w/v) sodium citrate solution 6 -
Figure 6 and7 shows results of citric acid and iron concentrations.
Plasma Cre and BUN concentrations increased markedly at 24 hours after extirpation of bilateral kidneys, and onset of renal failure was confirmed.
Plasma citric acid concentrations were 5.27 ± 1.23 mg/dL in the first group but increased to 16.38 ± 9.49 mg/dL and 17.11 ± 18.64 mg/dL in the second and third groups respectively due to extirpation of bilateral kidneys (Figure 6 ). The difference of plasma citric acid concentrations between before and after administration in the third group was 21.08 ± 13.18 mg/dL. Enhancement of plasma citric acid concentrations by administration of citric acid was observed. In contrast, the difference of plasma citric acid concentrations between before and after administration was -0.92 ± 2.20 mg/dL in the second group, indicating slight decreases in plasma citric acid concentrations.
Plasma iron concentrations were 112 ± 14 µg/dL in the first group but were 61 ± 17 µg/dL in the second group, indicating decreases due to renal failure state (Figure 7 ). Onset of iron metabolism abnormality in the second group models was speculated. In the third group administered with citric acid, the difference of plasma iron concentrations between before and after administration was maintained at higher levels (14-18 µg/dL) than that of second group (Δ5 ± 17 µg/dL) (Figure 7 ). It is indicated that plasma iron concentration can be enhanced by improved iron enclosure due to administration of citric acid. - Effects of citric acid administration in a dialysis session dialysis on iron metabolism in rat at the second day after extirpation of bilateral kidneys were evaluated.
- Examinations were performed in male CD(SD) rats in the groups in Table 4. After intra-peritoneal administration of pentobarbital sodium (50 mg/kg) for anesthesia, bilateral total kidneys were extirpated from the back of rat.
At the second day after operation, after intra-peritoneal administration of pentobarbital sodium (50 mg/kg) for anesthesia, catheters were placed in the left femoral artery and vein to create blood access, and a central venous catheter (CVC) was placed for citric acid administration as well as blood collection. After 1 mL of blood was collected by CVC, dialysis was performed for 4 hours with a commercial dialysate (AK-Solita·DL) under anesthesia. In the second and third groups of Table 4, physiological saline or a 4.5% (w/v) sodium citrate solution was administered by CVC at 1.0 mL/h continuously, and 1 mL of blood was collected by CVC immediately after termination of dialysis.
Collected blood was centrifuged in a refrigerated centrifuge to measure plasma creatinine (Cre), blood urea nitrogen (BUN), iron and citric acid. -
Table 4 Group Experimental Group Administered Solution Number of Animals 1 Bilateral kidney extirpation - 3 2 Bilateral kidney extirpation + Dialysis + Saline Physiological saline 2 3 Bilateral kidney extirpation + Dialysis + 4.5% Cit. 4.5% (w/v) Sodium citrate solution 2 -
Figures 8 and9 show results of citric acid and iron concentrations.
Plasma Cre and BUN concentrations increased markedly at the second day after extirpation of bilateral kidneys before dialysis, and onset of renal failure was confirmed. Increased plasma Cre and BUN concentrations decreased immediately by dialysis.
Plasma citric acid concentrations were 5.33 mg/dL in the first group but increased to 9.87 mg/dL in the second group due to extirpation of bilateral kidneys, while plasma citric acid concentrations in the third group were 5.33 mg/dL at the same level as the first group (Figure 8 ). In the third group administered with citric acid during dialysis, the difference of plasma citric acid concentrations between before and after citric acid administration was 26.49 mg/dL. Enhancement of plasma citric acid concentrations by administration of citric acid was observed. In contrast, in the second group administered with physiological saline during dialysis, the difference of plasma citric acid concentrations between before and after administration was -13.05 mg/dL, indicating slight decreases in plasma citric acid concentrations.
Plasma iron concentrations were 59 µg/dL in the first group, 113 µg/dL in the second group and 83 µg/dL in the third group. Although there were slight differences among the groups, decreases of plasma iron concentrations due to renal failure state induced by extirpation of bilateral kidneys were observed (Figure 9 ). In the third group administered with citric acid during dialysis, the difference of plasma iron concentrations between before and after administration was maintained at about 4 times higher (81 µg/dL) than that of second group (Δ19.5 µg/dL) (Figure 9 ). It is indicated that plasma iron concentration can be enhanced by improvement in iron enclosure due to administration of citric acid. -
Preparation A (component and amount per 10 L) Sodium chloride 2,148.0 g Potassium chloride 52.0 g Calcium chloride 77.0 g Magnesium chloride 36.0 g Glucose 525.0 g Citric acid 34.3 g Sodium citrate 10.3 g Preparation B (component and amount per 12.6 L) Sodium hydrogencarbonate 1,030.0 g -
Preparation A (component and amount per 1,010 mL) Sodium chloride 12.34 g Potassium chloride 0.30 g Sodium hydrogencarbonate 5.94 g Preparation B (component and amount per 1,010 mL) Calcium chloride 519.8 mg Magnesium chloride 205.4 mg Glucose 2.02 g Citric acid 198.0 mg Sodium citrate 59.4 mg - As aforementioned, according to the present invention, an acetic acid- and/or acetate salt-free iron metabolism improving agent containing citric acid and/or a citrate salt prevents hypercytokinemia, corrects iron transport protein dysregulation and releases "iron enclosure" in the reticuloendothelial system, which leads to enhancement of serum iron concentrations and improvement in iron recycle in a chronic renal failure patient receiving blood purification therapy. As a result, EPO-resistant renal anemia of such a patient is improved, and complication occurrence risks are reduced. Hence, the present invention has great medical advantages and usefulness for its contribution to improvement of QOL and prognosis of patients.
-
-
Figure 1 shows the results of plasma citric acid concentrations in Example 1. -
Figure 2 shows the results of serum iron concentrations in Example 1. -
Figure 3 shows the results of UIBC in Example 1. -
Figure 4 shows the results of TIBC in Example 1. -
Figure 5 shows the results of iron stein of splenic tissues. -
Figure 6 shows the results of plasma citric acid concentrations in Example 2. -
Figure 7 shows the results of plasma iron concentrations in Example 2. -
Figure 8 shows the results of plasma citric acid concentrations in Example 3. -
Figure 9 shows the results of plasma iron concentrations in Example 3.
Claims (10)
- An iron metabolism-improving agent comprising citric acid and/or a citrate salt.
- The iron metabolism-improving agent according to claim 1 comprising citric acid and/or a citrate salt as electrolytes.
- The iron metabolism-improving agent according to claim 1 or 2 comprising no acetic acid and/or an acetate salt and comprising citric acid and/or a citrate salt as electrolytes.
- The iron metabolism-improving agent according to claim 1, 2 or 3 comprising citric acid and/or a citrate salt as electrolytes and also comprising solely or in combination another/other electrolyte/electrolytes and glucose.
- The iron metabolism-improving agent according to any one of claims 1 to 4 formulated into a dialysate.
- The iron metabolism-improving agent according to any one of claims 2 to 4 formulated into a substitution fluid.
- A method for improving iron metabolism in a chronic renal failure patient receiving blood purification therapy such as hemodialysis, hemofiltration and hemodiafiltration, by administration of an iron metabolism-improving agent according to any one of claims 1 to 4.
- A method for improving iron metabolism in a chronic renal failure patient receiving blood purification therapy such as hemodialysis, hemofiltration and hemodiafiltration employing a dialysate and/or a substitution fluid containing the iron metabolism-improving agent according to claim 5 or 6.
- A blood purification method including hemodialysis and hemodiafiltration in a chronic renal failure patient employing a dialysate containing the iron metabolism-improving agent according to claim 5.
- A blood purification method including hemodiafiltration and hemofiltration in a chronic renal failure patient employing a substitution fluid containing the iron metabolism-improving agent according to claim 6.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006334294 | 2006-12-12 | ||
JP2007079488 | 2007-03-26 | ||
PCT/JP2007/073766 WO2008072591A1 (en) | 2006-12-12 | 2007-12-10 | Iron metabolism-improving agent |
Publications (4)
Publication Number | Publication Date |
---|---|
EP2123270A1 true EP2123270A1 (en) | 2009-11-25 |
EP2123270A4 EP2123270A4 (en) | 2010-07-07 |
EP2123270B1 EP2123270B1 (en) | 2012-08-29 |
EP2123270B2 EP2123270B2 (en) | 2016-06-15 |
Family
ID=39511611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07850340.6A Not-in-force EP2123270B2 (en) | 2006-12-12 | 2007-12-10 | Iron metabolism-improving agent |
Country Status (7)
Country | Link |
---|---|
US (2) | US20090306002A1 (en) |
EP (1) | EP2123270B2 (en) |
JP (2) | JP5592609B2 (en) |
KR (1) | KR101467957B1 (en) |
CN (2) | CN105640930A (en) |
TW (1) | TWI440457B (en) |
WO (1) | WO2008072591A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2123270B2 (en) † | 2006-12-12 | 2016-06-15 | Advanced Renal Technologies, Inc. | Iron metabolism-improving agent |
US9452149B2 (en) | 2012-03-08 | 2016-09-27 | Gambro Lundia Ab | Dialysis composition comprising citrate, calcium and magnesium |
US9463202B2 (en) | 2011-12-21 | 2016-10-11 | Gambro Lundia Ab | Dialysis precursor composition |
US9616161B2 (en) | 2011-06-20 | 2017-04-11 | Gambro Lundia Ab | Dialysis precursor composition |
US9821102B2 (en) | 2011-06-20 | 2017-11-21 | Gambro Lundia Ab | Dialysis precursor composition |
US9833470B2 (en) | 2011-12-21 | 2017-12-05 | Gambro Lundia Ab | Dialysis precursor composition |
EP3219315A4 (en) * | 2015-03-20 | 2017-12-06 | Hernández Miramontes, Jorge Antonio | Mixture of carboxylic acids for treating patients with kidney failure |
US9925155B2 (en) | 2012-12-18 | 2018-03-27 | Gambro Lundia Ab | Dialysis composition |
US10993961B2 (en) | 2010-06-23 | 2021-05-04 | Gambro Lundia Ab | Dialysis precursor composition |
US11253543B2 (en) | 2010-06-23 | 2022-02-22 | Gambro Lundia Ab | Dialysis precursor composition product |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7395288B2 (en) * | 2019-08-30 | 2023-12-11 | ポッカサッポロフード&ビバレッジ株式会社 | Angiotensin II Type 1 receptor antagonist |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020004530A1 (en) * | 2000-05-24 | 2002-01-10 | Warnock David G. | Use of citrate-containing dialysate for renal dialysis treatment |
WO2005094918A1 (en) * | 2004-03-30 | 2005-10-13 | Nipro Corporation | Solid pharmaceutical preparation for dialysis |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869458A (en) * | 1994-10-14 | 1999-02-09 | Waite; Christopher S. | Frozen rehydration formulation and delivery system therefor |
US5624668A (en) * | 1995-09-29 | 1997-04-29 | Luitpold Pharmaceuticals, Inc. | Iron dextran formulations |
US5906978A (en) † | 1996-08-14 | 1999-05-25 | Hemocleanse, Inc. | Method for iron delivery to a patient by transfer from dialysate |
JP3619921B2 (en) * | 1996-09-13 | 2005-02-16 | 富田製薬株式会社 | Bicarbonate solid dialysis agent |
US6779468B1 (en) † | 1997-08-07 | 2004-08-24 | Ajay Gupta | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients |
US7670491B2 (en) † | 1998-10-20 | 2010-03-02 | Advanced Renal Technologies | Buffered compositions for dialysis |
AU6605100A (en) † | 1999-06-30 | 2001-01-31 | Ajay Gupta | Method and pharmaceutical composition for parenteral administration of iron |
PT1218039E (en) * | 1999-09-22 | 2009-05-25 | Advanced Renal Technologies | Use of high citrate dialysate |
US6706007B2 (en) * | 2000-12-29 | 2004-03-16 | Chf Solutions, Inc. | Feedback control of ultrafiltration to prevent hypotension |
JP5204359B2 (en) * | 2001-09-28 | 2013-06-05 | 味の素株式会社 | Dialysis agent and method for producing the same |
CN101123987A (en) * | 2005-01-07 | 2008-02-13 | 味之素株式会社 | Dialysis preparation |
EP1890686B1 (en) * | 2005-05-30 | 2017-10-04 | Fresenius Medical Care Deutschland GmbH | Peritoneal dialysis fluid |
CN105640930A (en) † | 2006-12-12 | 2016-06-08 | 味之素株式会社 | Iron metabolism-improving agent |
-
2007
- 2007-12-10 CN CN201610085612.4A patent/CN105640930A/en active Pending
- 2007-12-10 KR KR1020097014516A patent/KR101467957B1/en not_active IP Right Cessation
- 2007-12-10 CN CN201510666104.0A patent/CN105380936A/en active Pending
- 2007-12-10 TW TW096147002A patent/TWI440457B/en not_active IP Right Cessation
- 2007-12-10 WO PCT/JP2007/073766 patent/WO2008072591A1/en active Application Filing
- 2007-12-10 JP JP2008549294A patent/JP5592609B2/en active Active
- 2007-12-10 EP EP07850340.6A patent/EP2123270B2/en not_active Not-in-force
-
2009
- 2009-06-11 US US12/482,723 patent/US20090306002A1/en not_active Abandoned
-
2013
- 2013-01-15 US US13/741,721 patent/US20130131179A1/en not_active Abandoned
-
2014
- 2014-06-27 JP JP2014132719A patent/JP2014218504A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020004530A1 (en) * | 2000-05-24 | 2002-01-10 | Warnock David G. | Use of citrate-containing dialysate for renal dialysis treatment |
WO2005094918A1 (en) * | 2004-03-30 | 2005-10-13 | Nipro Corporation | Solid pharmaceutical preparation for dialysis |
Non-Patent Citations (1)
Title |
---|
See also references of WO2008072591A1 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2123270B2 (en) † | 2006-12-12 | 2016-06-15 | Advanced Renal Technologies, Inc. | Iron metabolism-improving agent |
US11253543B2 (en) | 2010-06-23 | 2022-02-22 | Gambro Lundia Ab | Dialysis precursor composition product |
US10993961B2 (en) | 2010-06-23 | 2021-05-04 | Gambro Lundia Ab | Dialysis precursor composition |
US9616161B2 (en) | 2011-06-20 | 2017-04-11 | Gambro Lundia Ab | Dialysis precursor composition |
US9655922B1 (en) | 2011-06-20 | 2017-05-23 | Gambro Lundia Ab | Dialysis precursor composition |
US9821102B2 (en) | 2011-06-20 | 2017-11-21 | Gambro Lundia Ab | Dialysis precursor composition |
US10172881B2 (en) | 2011-12-21 | 2019-01-08 | Gambro Lundia Ab | Dialysis precursor composition |
US9463202B2 (en) | 2011-12-21 | 2016-10-11 | Gambro Lundia Ab | Dialysis precursor composition |
US9687507B2 (en) | 2011-12-21 | 2017-06-27 | Gambro Lundia Ab | Dialysis precursor composition |
US9833470B2 (en) | 2011-12-21 | 2017-12-05 | Gambro Lundia Ab | Dialysis precursor composition |
US9724298B2 (en) | 2012-03-08 | 2017-08-08 | Gambro Lundia Ab | Method to form a dialysis composition comprising citrate, calcium and magnesium |
US9452149B2 (en) | 2012-03-08 | 2016-09-27 | Gambro Lundia Ab | Dialysis composition comprising citrate, calcium and magnesium |
US9925155B2 (en) | 2012-12-18 | 2018-03-27 | Gambro Lundia Ab | Dialysis composition |
EP3219315A4 (en) * | 2015-03-20 | 2017-12-06 | Hernández Miramontes, Jorge Antonio | Mixture of carboxylic acids for treating patients with kidney failure |
Also Published As
Publication number | Publication date |
---|---|
WO2008072591A1 (en) | 2008-06-19 |
EP2123270B1 (en) | 2012-08-29 |
TWI440457B (en) | 2014-06-11 |
US20130131179A1 (en) | 2013-05-23 |
KR101467957B1 (en) | 2014-12-02 |
KR20090100390A (en) | 2009-09-23 |
CN105380936A (en) | 2016-03-09 |
JP2014218504A (en) | 2014-11-20 |
EP2123270A4 (en) | 2010-07-07 |
TW200833320A (en) | 2008-08-16 |
JPWO2008072591A1 (en) | 2010-03-25 |
CN105640930A (en) | 2016-06-08 |
JP5592609B2 (en) | 2014-09-17 |
US20090306002A1 (en) | 2009-12-10 |
EP2123270B2 (en) | 2016-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2123270B2 (en) | Iron metabolism-improving agent | |
EP1218039B1 (en) | Use of high citrate dialysate | |
Macdougall et al. | A randomized controlled study of iron supplementation in patients treated with erythropoietin | |
US6214802B1 (en) | Peritoneal dialysis fluid | |
EP2413944B1 (en) | A multipart fluid system and a system for regional citrate anticoagulation in an extracorporeal blood circuit | |
US6743191B1 (en) | Substitution infusion fluid and citrate anticoagulation | |
EP2119438B1 (en) | Bone metabolism ameliorating agent | |
EP1946763B1 (en) | Promoter for recovery from anesthesia | |
JP2021169525A (en) | Methods for treating iron deficiency using soluble ferric pyrophosphate | |
WO2010112570A1 (en) | Dialysis solution | |
JP2003511413A (en) | Use of L-carnitine and its alkanoyl derivatives as osmotic agents in solution for pharmaceutical use | |
EA002479B1 (en) | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients | |
Charytan et al. | Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients | |
Christiansson et al. | Treatment of severe ethylene glycol intoxication with continuous arteriovenous hemofiltration dialysis | |
ARfiFR | Anion gap: may the anions restricted to the intravascular space undergo modification in their valence? | |
CN101568334A (en) | Iron metabolism-improving agent | |
Bergmann et al. | Iron metabolism under rEPO therapy in patients on maintenance hemodialysis | |
EP2994123A1 (en) | Dialysis formulation | |
Michaud et al. | Four percent trisodium citrate as an alternative anticoagulant for maintaining patency of central venous hemodialysis catheters: case report and discussion | |
Tsukamoto et al. | Fatal hyperkalemia due to rapid red cell transfusion in a critically ill patient | |
EP1897535A1 (en) | Substitution fluid for haemofiltration | |
Forrest et al. | Parenteral nutrition in acute renal failure | |
EP1977773A1 (en) | Ameliorating agent for aluminum storage disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090630 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100608 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/26 20060101ALI20100601BHEP Ipc: A61K 47/02 20060101ALI20100601BHEP Ipc: A61K 9/08 20060101ALI20100601BHEP Ipc: A61P 43/00 20060101ALI20100601BHEP Ipc: A61P 13/12 20060101ALI20100601BHEP Ipc: A61P 7/06 20060101ALI20100601BHEP Ipc: A61P 3/02 20060101ALI20100601BHEP Ipc: A61K 31/194 20060101AFI20080710BHEP Ipc: A61P 7/08 20060101ALI20100601BHEP |
|
17Q | First examination report despatched |
Effective date: 20110609 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ADVANCED RENAL TECHNOLOGIES, INC. |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 572663 Country of ref document: AT Kind code of ref document: T Effective date: 20120915 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602007025186 Country of ref document: DE Effective date: 20121025 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 572663 Country of ref document: AT Kind code of ref document: T Effective date: 20120829 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D Effective date: 20120829 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121229 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120829 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120829 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120829 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120829 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120829 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120829 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120829 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121130 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120829 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120829 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120829 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121210 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120829 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120829 |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
PLAX | Notice of opposition and request to file observation + time limit sent |
Free format text: ORIGINAL CODE: EPIDOSNOBS2 |
|
26 | Opposition filed |
Opponent name: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH Effective date: 20130529 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121231 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121129 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R026 Ref document number: 602007025186 Country of ref document: DE Effective date: 20130529 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121210 |
|
PLAF | Information modified related to communication of a notice of opposition and request to file observations + time limit |
Free format text: ORIGINAL CODE: EPIDOSCOBS2 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120829 |
|
PLBB | Reply of patent proprietor to notice(s) of opposition received |
Free format text: ORIGINAL CODE: EPIDOSNOBS3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120829 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121210 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20071210 |
|
APBM | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOSNREFNO |
|
APBP | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2O |
|
APAH | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNO |
|
APBQ | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3O |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
R26 | Opposition filed (corrected) |
Opponent name: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH Effective date: 20130529 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
APBU | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9O |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20151126 Year of fee payment: 9 |
|
26 | Opposition filed |
Opponent name: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH Effective date: 20130529 |
|
PLBP | Opposition withdrawn |
Free format text: ORIGINAL CODE: 0009264 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20151126 Year of fee payment: 9 |
|
PUAH | Patent maintained in amended form |
Free format text: ORIGINAL CODE: 0009272 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: PATENT MAINTAINED AS AMENDED |
|
27A | Patent maintained in amended form |
Effective date: 20160615 |
|
AK | Designated contracting states |
Kind code of ref document: B2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: AELC Ref country code: DE Ref legal event code: R102 Ref document number: 602007025186 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: NAV |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161231 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161231 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20171127 Year of fee payment: 11 Ref country code: DE Payment date: 20171127 Year of fee payment: 11 Ref country code: CZ Payment date: 20171128 Year of fee payment: 11 Ref country code: FR Payment date: 20171127 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20171121 Year of fee payment: 11 Ref country code: IT Payment date: 20171128 Year of fee payment: 11 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161211 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602007025186 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181210 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20190101 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20181210 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190101 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181231 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181210 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190702 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181210 |